Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis
the research work was conducted for the pharmacoeconomic evaluation and optimization of fluid therapy for patients, suffering from peritonitis disease. Reamberin, Ringer's solution, Plasma-Lyte and Sterofundin drugs were compared during the analysis. A cost analysis, cost-effectiveness analysis...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2015-03-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/46 |
| _version_ | 1797878920770486272 |
|---|---|
| author | R. I. Yagudina M. M. Murashko |
| author_facet | R. I. Yagudina M. M. Murashko |
| author_sort | R. I. Yagudina |
| collection | DOAJ |
| description | the research work was conducted for the pharmacoeconomic evaluation and optimization of fluid therapy for patients, suffering from peritonitis disease. Reamberin, Ringer's solution, Plasma-Lyte and Sterofundin drugs were compared during the analysis. A cost analysis, cost-effectiveness analysis, budget impact analysis and sensitivity analysis were conducted. The survival rate of patients was used as the effectiveness criterion. The CER amounted to 440,759 roubles for Reamberin, 543,991 roubles for the Ringer's solution, 529,498 roubles for Plasma-Lyte and 502,842 roubles for Sterofundin. The analysis showed that the scheme of peritonitis therapy included Reamberin is the dominant. The « budget impact» analysis was carried out from the perspective of health care facilities. The budget impact analysis shown that the 100% switching patients to Reamberin saves respectively: from the Ringer’s solution 5,654,594 roubles, from Plasma-Lyte 2,215,117 roubles and from Sterofundin 2,218,280 roubles. For the interpretation of the survey data for a particular health facility pharmacoeconomic simulation model was designed. |
| first_indexed | 2024-04-10T02:40:50Z |
| format | Article |
| id | doaj.art-09f647ec71a74482b66a415c84a14829 |
| institution | Directory Open Access Journal |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| last_indexed | 2024-04-10T02:40:50Z |
| publishDate | 2015-03-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj.art-09f647ec71a74482b66a415c84a148292023-03-13T07:48:14ZrusIRBIS LLCФармакоэкономика2070-49092070-49332015-03-0164212540Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitisR. I. Yagudina0M. M. Murashko1First Moscow State Medical University named after I.M. SechenovFirst Moscow State Medical University named after I.M. Sechenovthe research work was conducted for the pharmacoeconomic evaluation and optimization of fluid therapy for patients, suffering from peritonitis disease. Reamberin, Ringer's solution, Plasma-Lyte and Sterofundin drugs were compared during the analysis. A cost analysis, cost-effectiveness analysis, budget impact analysis and sensitivity analysis were conducted. The survival rate of patients was used as the effectiveness criterion. The CER amounted to 440,759 roubles for Reamberin, 543,991 roubles for the Ringer's solution, 529,498 roubles for Plasma-Lyte and 502,842 roubles for Sterofundin. The analysis showed that the scheme of peritonitis therapy included Reamberin is the dominant. The « budget impact» analysis was carried out from the perspective of health care facilities. The budget impact analysis shown that the 100% switching patients to Reamberin saves respectively: from the Ringer’s solution 5,654,594 roubles, from Plasma-Lyte 2,215,117 roubles and from Sterofundin 2,218,280 roubles. For the interpretation of the survey data for a particular health facility pharmacoeconomic simulation model was designed.https://www.pharmacoeconomics.ru/jour/article/view/46pharmacoeconomicscost analysisan analysis of the “cost-effectiveness”analysis of the “impact on the budget”peritonitisreamberin |
| spellingShingle | R. I. Yagudina M. M. Murashko Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis Фармакоэкономика pharmacoeconomics cost analysis an analysis of the “cost-effectiveness” analysis of the “impact on the budget” peritonitis reamberin |
| title | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis |
| title_full | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis |
| title_fullStr | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis |
| title_full_unstemmed | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis |
| title_short | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis |
| title_sort | pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis |
| topic | pharmacoeconomics cost analysis an analysis of the “cost-effectiveness” analysis of the “impact on the budget” peritonitis reamberin |
| url | https://www.pharmacoeconomics.ru/jour/article/view/46 |
| work_keys_str_mv | AT riyagudina pharmacoeconomicanalysisoffluidtherapyinthetreatmentofpatientswithperitonitis AT mmmurashko pharmacoeconomicanalysisoffluidtherapyinthetreatmentofpatientswithperitonitis |